Sanara MedTech Inc. (SMTI)
USD 31.79
(-6.47%)
USD 31.79
(-6.47%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 57.13 Million USD | 35.41% |
| 2022 | 39.48 Million USD | 80.84% |
| 2021 | 21.83 Million USD | 56.28% |
| 2020 | 13.97 Million USD | 32.33% |
| 2019 | 10.55 Million USD | 98.06% |
| 2018 | 5.33 Million USD | -3.06% |
| 2017 | 5.49 Million USD | 20.47% |
| 2016 | 4.56 Million USD | 84.03% |
| 2015 | 2.48 Million USD | 35.6% |
| 2014 | 1.82 Million USD | 95.91% |
| 2013 | 933.61 Thousand USD | 148.96% |
| 2012 | 375.01 Thousand USD | -73.4% |
| 2011 | 1.41 Million USD | 278.9% |
| 2010 | 372.14 Thousand USD | 145.54% |
| 2009 | -817.2 Thousand USD | -543.9% |
| 2008 | -126.91 Thousand USD | -131.16% |
| 2007 | 407.32 Thousand USD | 12435.58% |
| 2006 | -3302.00 USD | 94.51% |
| 2005 | -60.17 Thousand USD | -1201.85% |
| 2004 | 5461.00 USD | 0.0% |
| 2001 | 1010.00 USD | -99.87% |
| 2000 | 791.74 Thousand USD | -4.38% |
| 1999 | 828.04 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 15.54 Million USD | 4.96% |
| 2024 Q2 | 17.04 Million USD | 16.79% |
| 2023 Q3 | 14.27 Million USD | 5.22% |
| 2023 Q4 | 14.8 Million USD | 3.74% |
| 2023 FY | 53.46 Million USD | 35.41% |
| 2023 Q2 | 13.56 Million USD | 1.26% |
| 2023 Q1 | 13.39 Million USD | 3.47% |
| 2022 Q1 | 7 Million USD | 12.09% |
| 2022 Q2 | 8.71 Million USD | 24.36% |
| 2022 Q4 | 12.94 Million USD | 19.7% |
| 2022 Q3 | 10.81 Million USD | 24.14% |
| 2022 FY | 39.48 Million USD | 80.84% |
| 2021 Q2 | 5.74 Million USD | 26.59% |
| 2021 FY | 21.83 Million USD | 56.28% |
| 2021 Q3 | 5.3 Million USD | -7.57% |
| 2021 Q4 | 6.25 Million USD | 17.8% |
| 2021 Q1 | 4.53 Million USD | 5.48% |
| 2020 Q3 | 3.85 Million USD | 47.35% |
| 2020 Q2 | 2.61 Million USD | -18.02% |
| 2020 Q4 | 4.29 Million USD | 11.43% |
| 2020 FY | 13.97 Million USD | 32.33% |
| 2020 Q1 | 3.19 Million USD | 4.62% |
| 2019 Q2 | 2.68 Million USD | 22.07% |
| 2019 FY | 10.55 Million USD | 98.06% |
| 2019 Q4 | 3.05 Million USD | 16.35% |
| 2019 Q3 | 2.62 Million USD | -2.18% |
| 2019 Q1 | 2.19 Million USD | 8718.44% |
| 2018 Q3 | 1.45 Million USD | -31.06% |
| 2018 Q2 | 2.1 Million USD | 20.17% |
| 2018 Q1 | 1.75 Million USD | 19.95% |
| 2018 FY | 5.33 Million USD | -3.06% |
| 2018 Q4 | 24.92 Thousand USD | -98.28% |
| 2017 Q4 | 1.45 Million USD | 10.66% |
| 2017 Q1 | 1.43 Million USD | 1.23% |
| 2017 Q3 | 1.31 Million USD | 2.36% |
| 2017 Q2 | 1.28 Million USD | -9.99% |
| 2017 FY | 5.49 Million USD | 20.47% |
| 2016 Q3 | 1.19 Million USD | 14.34% |
| 2016 Q1 | 904.58 Thousand USD | 107.92% |
| 2016 Q2 | 1.04 Million USD | 15.82% |
| 2016 FY | 4.56 Million USD | 84.03% |
| 2016 Q4 | 1.41 Million USD | 18.05% |
| 2015 Q2 | 539.76 Thousand USD | -32.27% |
| 2015 Q3 | 708.49 Thousand USD | 31.26% |
| 2015 FY | 2.48 Million USD | 35.6% |
| 2015 Q1 | 796.9 Thousand USD | 33.58% |
| 2015 Q4 | 435.05 Thousand USD | -38.6% |
| 2014 Q4 | 596.58 Thousand USD | 34.38% |
| 2014 Q3 | 443.95 Thousand USD | 61.49% |
| 2014 Q2 | 274.9 Thousand USD | -46.47% |
| 2014 Q1 | 513.57 Thousand USD | 45.09% |
| 2014 FY | 1.82 Million USD | 95.91% |
| 2013 Q3 | 234.01 Thousand USD | 25.82% |
| 2013 Q2 | 185.99 Thousand USD | 16.52% |
| 2013 Q1 | 159.63 Thousand USD | -1.58% |
| 2013 FY | 933.61 Thousand USD | 148.96% |
| 2013 Q4 | 353.97 Thousand USD | 51.26% |
| 2012 FY | 375.01 Thousand USD | -73.4% |
| 2012 Q4 | 162.19 Thousand USD | 7.54% |
| 2012 Q3 | 150.82 Thousand USD | 97.92% |
| 2012 Q2 | 76.2 Thousand USD | 636.43% |
| 2012 Q1 | -14.2 Thousand USD | -102.13% |
| 2011 Q1 | 840.99 Thousand USD | 97.88% |
| 2011 FY | 1.41 Million USD | 278.9% |
| 2011 Q4 | 665.76 Thousand USD | 377.79% |
| 2011 Q3 | -239.66 Thousand USD | -267.41% |
| 2011 Q2 | 143.16 Thousand USD | -82.98% |
| 2010 FY | 372.14 Thousand USD | 145.54% |
| 2010 Q1 | 46.29 Thousand USD | 108.65% |
| 2010 Q2 | 86.55 Thousand USD | 86.98% |
| 2010 Q3 | -184.98 Thousand USD | -313.72% |
| 2010 Q4 | 424.99 Thousand USD | 329.74% |
| 2009 Q2 | -60.55 Thousand USD | 76.41% |
| 2009 Q3 | 4804.00 USD | 107.93% |
| 2009 Q1 | -256.71 Thousand USD | -246.71% |
| 2009 Q4 | -534.97 Thousand USD | -11236.05% |
| 2009 FY | -817.2 Thousand USD | -543.9% |
| 2008 Q4 | -74.04 Thousand USD | -362.08% |
| 2008 Q2 | 3841.00 USD | 104.52% |
| 2008 Q1 | -84.96 Thousand USD | -247.02% |
| 2008 FY | -126.91 Thousand USD | -131.16% |
| 2008 Q3 | 28.25 Thousand USD | 635.54% |
| 2007 Q2 | 189.66 Thousand USD | 233.08% |
| 2007 FY | 407.32 Thousand USD | 12435.58% |
| 2007 Q4 | 57.79 Thousand USD | -43.85% |
| 2007 Q3 | 102.92 Thousand USD | -45.73% |
| 2007 Q1 | 56.94 Thousand USD | 279.15% |
| 2006 Q2 | 5815.00 USD | -32.52% |
| 2006 Q1 | 8617.00 USD | 108.37% |
| 2006 Q3 | 13.06 Thousand USD | 124.61% |
| 2006 Q4 | -31.78 Thousand USD | -343.35% |
| 2006 FY | -3302.00 USD | 94.51% |
| 2005 FY | -60.17 Thousand USD | -1201.85% |
| 2005 Q4 | -102.99 Thousand USD | -619.3% |
| 2005 Q2 | 5045.00 USD | 74.09% |
| 2005 Q1 | 2898.00 USD | 106.8% |
| 2005 Q3 | 19.83 Thousand USD | 293.14% |
| 2004 Q4 | -42.64 Thousand USD | -580.1% |
| 2004 FY | 5461.00 USD | 0.0% |
| 2004 Q3 | 8883.00 USD | -68.84% |
| 2004 Q2 | 28.5 Thousand USD | 166.02% |
| 2004 Q1 | 10.71 Thousand USD | 0.0% |
| 2002 Q1 | - USD | 100.0% |
| 2001 Q4 | -699.02 Thousand USD | -882.68% |
| 2001 Q1 | 388.06 Thousand USD | 9.76% |
| 2001 FY | 1010.00 USD | -99.87% |
| 2001 Q3 | 89.31 Thousand USD | -30.97% |
| 2001 Q2 | 129.38 Thousand USD | -66.66% |
| 2000 FY | 791.74 Thousand USD | -4.38% |
| 2000 Q2 | 14.08 Thousand USD | -95.25% |
| 2000 Q3 | 127.74 Thousand USD | 806.81% |
| 2000 Q1 | 296.37 Thousand USD | 0.0% |
| 2000 Q4 | 353.54 Thousand USD | 176.77% |
| 1999 FY | 828.04 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 56.3 Million USD | -1.478% |
| AngioDynamics, Inc. | 154.69 Million USD | 63.065% |
| AtriCure, Inc. | 300.37 Million USD | 80.978% |
| Avinger, Inc. | 2 Million USD | -2752.579% |
| Azenta, Inc. | 263.14 Million USD | 78.286% |
| BioLife Solutions, Inc. | 46.75 Million USD | -22.213% |
| The Cooper Companies, Inc. | 2.35 Billion USD | 97.577% |
| Daxor Corporation | 1.1 Million USD | -5078.094% |
| Ekso Bionics Holdings, Inc. | 9.07 Million USD | -529.333% |
| Femasys Inc. | 691.9 Thousand USD | -8157.996% |
| GlucoTrack, Inc. | -13 Thousand USD | 439616.577% |
| Harvard Bioscience, Inc. | 60.86 Million USD | 6.126% |
| Hologic, Inc. | 2.22 Billion USD | 97.435% |
| ICU Medical, Inc. | 739.87 Million USD | 92.277% |
| Intuitive Surgical, Inc. | 4.72 Billion USD | 98.792% |
| KORU Medical Systems, Inc. | 16.7 Million USD | -241.969% |
| LeMaitre Vascular, Inc. | 127.04 Million USD | 55.027% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 47982.036% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 47982.036% |
| Masimo Corporation | 1 Billion USD | 94.306% |
| Microbot Medical Inc. | -106 Thousand USD | 54002.976% |
| Meihua International Medical Technologies Co., Ltd. | 33.09 Million USD | -72.646% |
| Merit Medical Systems, Inc. | 583.87 Million USD | 90.214% |
| Nephros, Inc. | 8.4 Million USD | -579.8% |
| NovoCure Limited | 381.05 Million USD | 85.006% |
| NEXGEL, Inc. | 619 Thousand USD | -9130.558% |
| NEXGEL, Inc. | 619 Thousand USD | -9130.558% |
| Singular Genomics Systems, Inc. | -558 Thousand USD | 10339.634% |
| OraSure Technologies, Inc. | 179.42 Million USD | 68.155% |
| Pro-Dex, Inc. | 14.55 Million USD | -292.668% |
| Pulse Biosciences, Inc. | -1.2 Million USD | 4833.816% |
| Predictive Oncology Inc. | 1.14 Million USD | -4888.85% |
| Precision Optics Corporation, Inc. | 5.79 Million USD | -885.501% |
| QuidelOrtho Corporation | 1.49 Billion USD | 96.177% |
| Repligen Corporation | 315.22 Million USD | 81.874% |
| STAAR Surgical Company | 252.65 Million USD | 77.385% |
| Sharps Technology, Inc. | -891.24 Thousand USD | 6510.915% |
| Utah Medical Products, Inc. | 30.03 Million USD | -90.216% |
| DENTSPLY SIRONA Inc. | 2.08 Billion USD | 97.261% |
| Jin Medical International Ltd. | 6.78 Million USD | -742.13% |